- Home
- COYA vs SLS Comparison
COYA vs SLS Comparison
Compare COYA & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- SLS
- Stock Information
- Founded
- COYA 2020
- SLS 2012
- Country
- COYA United States
- SLS United States
- Employees
- COYA N/A
- SLS N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- COYA Health Care
- SLS Health Care
- Exchange
- COYA Nasdaq
- SLS Nasdaq
- Market Cap
- COYA 108.4M
- SLS 89.6M
- IPO Year
- COYA 2022
- SLS N/A
- Fundamental
- Price
- COYA $6.31
- SLS $1.09
- Analyst Decision
- COYA Strong Buy
- SLS
- Analyst Count
- COYA 4
- SLS 0
- Target Price
- COYA $17.00
- SLS N/A
- AVG Volume (30 Days)
- COYA 85.7K
- SLS 815.8K
- Earning Date
- COYA 03-18-2025
- SLS 03-20-2025
- Dividend Yield
- COYA N/A
- SLS N/A
- EPS Growth
- COYA N/A
- SLS N/A
- EPS
- COYA N/A
- SLS N/A
- Revenue
- COYA $3,554,061.00
- SLS N/A
- Revenue This Year
- COYA $61.45
- SLS N/A
- Revenue Next Year
- COYA N/A
- SLS N/A
- P/E Ratio
- COYA N/A
- SLS N/A
- Revenue Growth
- COYA N/A
- SLS N/A
- 52 Week Low
- COYA $4.75
- SLS $0.77
- 52 Week High
- COYA $10.24
- SLS $1.84
- Technical
- Relative Strength Index (RSI)
- COYA 45.71
- SLS 40.56
- Support Level
- COYA $6.36
- SLS $1.13
- Resistance Level
- COYA $7.06
- SLS $1.25
- Average True Range (ATR)
- COYA 0.45
- SLS 0.07
- MACD
- COYA -0.03
- SLS -0.01
- Stochastic Oscillator
- COYA 20.21
- SLS 17.39
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.